Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Onvansertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 known ✓ | P53350 | 20/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 9/20 | 1.00 |
| ▸ | PLK2 | Q9NYY3 | 6/20 | 1.00 |
| ▸ | FLT3 | P36888 | 5/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | CSNK2B | P67870 | 1/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 1.00 |
| ▸ | MELK | Q14680 | 1/20 | 1.00 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.88 |
| ▸ | CDK2 | P24941 | 3/20 | 0.88 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.88 |
| ▸ | NEK6 | Q9HC98 | 3/20 | 0.84 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Onvansertib SCHEMBL29379736 | 1.00 | PLK1 (1.00) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| Onvansertib SCHEMBL29529814 | 0.96 | PLK1 (0.92) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL3503742 | 0.94 | PLK1 (1.00) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL3504256 | 0.94 | PLK1 (1.00) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL25623956 | 0.94 | PLK1 (0.88) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL3504873 | 0.94 | PLK1 (1.00) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL30777923 | 0.94 | PLK1 (0.88) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL13225438 | 0.94 | PLK1 (0.88) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL13225440 | 0.93 | PLK1 (1.00) | PLK1PLK3PLK2FLT3CSNK2A2 | |
| SCHEMBL3504610 | 0.93 | PLK1 (0.86) | PLK1PLK3PLK2FLT3CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 947 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946313-B1 | ONVANSERTIB FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | CARDIFF ONCOLOGY INC (US) | 2026-05-27 | — | — | EP | claimed |
| US-12637718-B2 | Predictive biomarkers for onvansertib treatment | CARDIFF ONCOLOGY, INC. (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | claimed |
| US-12630532-B2 | Indole-substituted quinolines and their combination with Plk1 inhibitors for the treatment of cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2026-05-19 | — | — | US | claimed |
| CN-122057044-A | Nanometer liposome delivery system for targeting PLK1/Aurora kinase and application thereof in oral squamous cell carcinoma treatment | 徐州医科大学 | 2026-05-19 | — | — | CN | claimed |
| EP-4735448-A1 | SUBSTITUTED SPIRO COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-05-06 | — | — | EP | claimed |
| US-20260116962-A1 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | CARDIFF ONCOLOGY INC (US) | 2026-04-30 | — | — | US | claimed |
| US-12606616-B2 | PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer | CARDIFF ONCOLOGY, INC. (US) | 2026-04-21 | — | — | US | claimed |
| US-20260103509-A1 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | CARDIFF ONCOLOGY INC (US) | 2026-04-16 | — | — | US | claimed |
| US-20260092327-A1 | METHODS OF MONITORING MUTATIONS IN TREATMENT OF COLORECTAL CANCER | CARDIFF ONCOLOGY INC (US) | 2026-04-02 | — | — | US | claimed |
| US-20220127682-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-28 | — | — | US | claimed |
| US-20220110941-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS | FELICITEX THERAPEUTICS, INC. | 2022-04-14 | — | — | US | claimed |
| WO-2022055721-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-17 | — | — | WO | claimed |
| CN-114096280-A | Therapeutic constructs for co-delivery of mitotic kinase inhibitors and immune checkpoint inhibitors | 俄勒冈健康与科学大学 | 2022-02-25 | — | — | CN | claimed |
| EP-3946313-A1 | PLK1 INHIBITORS AND PSA LEVELS IN PROSTATE CANCER | Cardiff Oncology, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| US-20180369214-A1 | Methods of Diagnosing and Treating Small Cell Lung Cancer Using Polo-Like Kinase 1 (PLK1) Inhibitors | EMORY UNIVERSITY | 2018-12-27 | — | — | US | claimed |
| US-8614220-B2 | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-12-24 | — | — | US | claimed |
| US-20100216808-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2010-08-26 | — | — | US | claimed |
| EP-2125822-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2009-12-02 | — | — | EP | claimed |
| WO-2008074788-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606616-B2 | PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer | PLK1, BUB1, BUB1B | PLK1 1/4885PLK3 10/4885PLK2 6/4885 |
| US-12637718-B2 | Predictive biomarkers for onvansertib treatment | SF3B1, SF3B5, U2AF1 | PLK1 23/4885PLK3 103/4885PLK2 57/4885 |
| US-20260103509-A1 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | PLK1, BUB1, AURKC | PLK1 1/4885PLK3 23/4885PLK2 6/4885 |
| US-20220127682-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | PLK4, PLK2, BUB1B | PLK1 5/4885PLK3 4/4885PLK2 2/4885 |
| US-20220110941-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS | BUB1B, BUB1, CCNB1 | PLK1 5/4885PLK3 370/4885PLK2 97/4885 |
| US-20260116962-A1 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | PLK1, PLK4, PLK2 | PLK1 1/4885PLK3 4/4885PLK2 3/4885 |
| US-20260092327-A1 | METHODS OF MONITORING MUTATIONS IN TREATMENT OF COLORECTAL CANCER | KRAS, HRAS, NRAS | PLK1 25/4885PLK3 103/4885PLK2 48/4885 |
| US-20100216808-A1 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | PLK1 91/4885PLK3 121/4885PLK2 30/4885 |
| US-12630532-B2 | Indole-substituted quinolines and their combination with Plk1 inhibitors for the treatment of cancer | PLK1, MYC, PLK4 | PLK1 1/4885PLK3 10/4885PLK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.